|
|
Volumn 10, Issue 1, 2010, Pages 25-32
|
|
Naltrexone/bupropion: Contrave®; Naltrexone SR/bupropion SR
[No Author Info available]
|
|
Author keywords
general; Naltrexonebupropion; Obesity; Opioid receptor antagonists general; Research and development; treatment
|
|
Indexed keywords
AMFEBUTAMONE;
BUPROPION PLUS NALTREXONE;
C REACTIVE PROTEIN;
CONTRAVE;
HIGH DENSITY LIPOPROTEIN;
NALTREXONE;
PLACEBO;
TRIACYLGLYCEROL;
UNCLASSIFIED DRUG;
ANXIETY;
ARTICLE;
BEHAVIOR MODIFICATION;
CARDIOVASCULAR RISK;
CHOLECYSTITIS;
DEPRESSION;
DIET THERAPY;
DIZZINESS;
DRUG INDUCED HEADACHE;
DRUG WITHDRAWAL;
ELECTROCARDIOGRAM;
EXERCISE;
FOOD INTAKE;
HUMAN;
INSOMNIA;
MAXIMUM PLASMA CONCENTRATION;
MONOTHERAPY;
NAUSEA;
NONHUMAN;
OBESITY;
PATIENT COUNSELING;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SIDE EFFECT;
SLEEP DISORDER;
SMOKING CESSATION;
SUSTAINED RELEASE FORMULATION;
TIME TO MAXIMUM PLASMA CONCENTRATION;
TOBACCO DEPENDENCE;
URTICARIA;
VITAL SIGN;
ANIMALS;
ANTI-OBESITY AGENTS;
BUPROPION;
CLINICAL TRIALS, PHASE II AS TOPIC;
CLINICAL TRIALS, PHASE III AS TOPIC;
DELAYED-ACTION PREPARATIONS;
DRUG COMBINATIONS;
DRUG EVALUATION, PRECLINICAL;
DRUGS, INVESTIGATIONAL;
HUMANS;
NALTREXONE;
OBESITY;
|
|
EID: 78349279128
PISSN: 11745886
EISSN: 11796901
Source Type: Journal
DOI: 10.2165/11537710-000000000-00000 Document Type: Article |
|
Times cited : (15)
|
|
References (29)
|
